Home > Healthcare > Pharmaceuticals > Finished Drug Form > Cephalosporin Drugs Market

Cephalosporin Drugs Market Share

Report ID: GMI8194
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Cephalosporin Drugs Market Share

The cephalosporin drugs industry is characterized by diverse players competing in the industry. Pfizer Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, and Novartis AG, account for significant market share. These prominent players adopt a combination of strategic initiatives such as collaboration & partnership, global expansion strategies, research and development, product diversification, and regulatory compliance to maintain a competitive edge in the market.

Cephalosporin Drugs Market Companies

Foremost players operating in the cephalosporin drugs industry are as mentioned below:

AbbVie Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global cephalosporin drugs industry was valued at USD 14.1 billion in 2023 and is estimated to grow at a CAGR of 3.1% between 2024 and 2032, attributed to growing number of generic medications, rising geriatric population, and advancements in drug discovery services.

The parenteral segment is expected to reach a notable market revenue of USD 11.3 billion by 2032, owing to the rapid and direct delivery of the drug into the bloodstream.

In 2023, North America held a significant share of 42.2% in the cephalosporin drugs market, backed by substantial investments in pharmaceuticals, including the purchase and use of cephalosporin drugs.

AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.